You are correct if I have read the Neuren report correctly.
Acadia anticipates potential approval of a New Drug Submission (NDS) filing for trofinetide in Canada around year-end 2024. There are currently 600 to 900 Rett patients in Canada. Any net sales in Canada will be included in the North America net sales for the purpose of calculating royalties and sales milestone payments to Neuren.
TROFINETIDE PRIORITY REVIEW IN CANADA, page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.21 |
Change
-1.060(4.98%) |
Mkt cap ! $2.583B | |||
| Open | High | Low | Value | Volume |
| $20.98 | $21.06 | $20.14 | $6.308M | 308.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3926 | $20.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.21 | 388 | 1 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |